Published in Arthritis Res Ther on June 21, 2004
Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence (2015) 0.92
A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol (2006) 0.88
New drug targets in inflammation: efforts to expand the anti-inflammatory armoury. Br J Pharmacol (2008) 0.78
Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int (2006) 0.76
The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag (2007) 0.76
[TNFalpha inhibitors in the treatment of uveitis]. Ophthalmologe (2005) 0.75
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 27.82
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 2.96
Risk of malignancy among patients with rheumatic conditions. Int J Cancer (2000) 2.70
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 2.12
The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol (2003) 2.06
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol (2001) 1.86
Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today (1997) 1.34
Human immune response to recombinant human proteins. J Pharm Sci (2001) 1.23
Therapeutic monoclonal antibodies. Lancet (2000) 1.17
Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum (1991) 1.17
The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum (1999) 1.13
Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol (1996) 1.12
Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther (1999) 1.12
Progress in the treatment of rheumatoid arthritis. JAMA (2001) 1.01
Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int (1996) 0.99
Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am (2001) 0.85
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum (2002) 1.61
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.37
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis (2007) 1.25
A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med (2011) 1.20
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol (2007) 1.13
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum (2002) 1.01
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol (2002) 0.96
Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol Interv (2003) 0.81
A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view. Ann Rheum Dis (2007) 0.81
Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. J Rheumatol (2008) 0.77
A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritis. Curr Med Res Opin (2007) 0.76